SCHEMBL3825660

SCHEMBL3825660

O=C(c1ccccc1C(F)(F)F)N1CCN(c2ccc(C#CCO)cn2)CC1

nearest known ligand 0.57

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SCD O00767 11/20 0.57
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
DCTPP1 Q9H773 2/20 0.50
GBA1 P04062 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3828698 0.89 SCD (0.58) SCDKDM4ELMNASMN1; SMN2GBA1
SCHEMBL3829390 0.89 SCD (0.59) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL3825613 0.89 SCD (0.59) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL5106995 0.88 SCD (0.59) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL3826413 0.87 SCD (0.55) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL3830773 0.87 SCD (0.55) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL3825117 0.86 SCD (0.51) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL14130757 0.86 SCD (0.51) SCDKDM4ELMNASMN1; SMN2DCTPP1
SCHEMBL3831513 0.86 SCD (0.56) SCDKDM4ELMNASMN1; SMN2GBA1
SCHEMBL3826477 0.86 SCD (0.56) SCDKDM4ELMNASMN1; SMN2GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099755-A2 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS Glenmark Pharmaceuticals S.A. (CH) 2009-09-16 EP claimed
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2008-07-31 US claimed
WO-2008062276-A2 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (US) 2008-05-29 WO claimed
EP-2099755-A2 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS Glenmark Pharmaceuticals S.A. (CH) 2009-09-16 EP disclosed
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2008-07-31 US disclosed
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2008-07-31 US disclosed
WO-2008062276-A2 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182851-A1 ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS SCD, SCD5, ACACA SCD 1/4885KDM4E 1815/4885LMNA 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.